NT5E and breast cancer: Interestingly, blockade of CAF-S1-dependent CD73 enzymatic activity by using a specific anti-CD73 antibody [39] impairs CAF-S1-mediated Tregs activation and immunosuppressive function, suggesting that BC patients might benefit from anti-CD73 immunotherapy.